A Nomogram Predicting Progression Free Survival in Patients with Gastrointestinal Stromal Tumor Receiving Sunitinib: Incorporating Pre-Treatment and Post-Treatment Parameters

SIMPLE SUMMARY: Sunitinib has been approved as the second-line targeted treatment for gastrointestinal stromal tumor (GIST) after imatinib failure. It is thus necessary to effectively assess prognosis after sunitinib use. However, the current assessment remains insufficient for the contemporary peri...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yau-Ren, Huang, Wen-Kuan, Wang, Shang-Yu, Wu, Chiao-En, Chen, Jen-Shi, Yeh, Chun-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197516/
https://www.ncbi.nlm.nih.gov/pubmed/34070456
http://dx.doi.org/10.3390/cancers13112587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197516/
https://www.ncbi.nlm.nih.gov/pubmed/34070456
http://dx.doi.org/10.3390/cancers13112587

Ejemplares similares